Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News HCW Biologics Inc HCWB

Healthcare Biotechnology
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat... see more

Recent & Breaking News (NDAQ:HCWB)

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

GlobeNewswire August 25, 2025

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

GlobeNewswire August 18, 2025

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

GlobeNewswire June 27, 2025

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

GlobeNewswire June 26, 2025

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

GlobeNewswire June 4, 2025

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

GlobeNewswire May 15, 2025

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

GlobeNewswire May 13, 2025

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

GlobeNewswire May 13, 2025

HCW Biologics Announces 1-for-40 Reverse Stock Split

GlobeNewswire April 1, 2025

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

GlobeNewswire March 28, 2025

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

GlobeNewswire March 6, 2025

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

GlobeNewswire February 3, 2025

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

GlobeNewswire January 15, 2025

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

GlobeNewswire December 23, 2024

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

GlobeNewswire November 18, 2024

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

GlobeNewswire November 18, 2024

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 14, 2024

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

GlobeNewswire August 23, 2024

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire August 14, 2024

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire May 15, 2024

Podcasts